AR031627A1 - Activadores heteroaromaticos fusionados de la glucoquinasa - Google Patents
Activadores heteroaromaticos fusionados de la glucoquinasaInfo
- Publication number
- AR031627A1 AR031627A1 ARP010105639A ARP010105639A AR031627A1 AR 031627 A1 AR031627 A1 AR 031627A1 AR P010105639 A ARP010105639 A AR P010105639A AR P010105639 A ARP010105639 A AR P010105639A AR 031627 A1 AR031627 A1 AR 031627A1
- Authority
- AR
- Argentina
- Prior art keywords
- glucoquinasa
- fusioned
- heteroaromatic
- activators
- halo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
Los compuestos activadores de la glucoquinasa o las sales farmacéuticamente aceptables de formula (1): en donde M es formulas (2) o (3), Q es formulas (4) o (5), R1 es un alquilo con C1-3; R2 es hidrogeno, halo, nitro, ciano, o perfluoro-metilo; R3 es un cicloalquilo con C4-7 o 2-propilo; R5 es halogeno; R6 es halogeno; W es O, S o NH; cada Y es independientemente CH o N; Z es ûCH2-CH2-CH2-CH2- o ûCH=CR4-CH=CH-, en donde R4 es hidrogeno, halo o una alquil sulfona con C1-3; y las líneas de puntos colectivamente representan 0 o 2 dobles enlaces adicionales en la estructura del anillo heterocíclico. Los compuestos de formula (1) también se pueden presentar en forma de racemato o en la configuracion "R" aislada en el carbono asimétrico mostrado.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25163700P | 2000-12-06 | 2000-12-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR031627A1 true AR031627A1 (es) | 2003-09-24 |
Family
ID=22952803
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP010105639A AR031627A1 (es) | 2000-12-06 | 2001-12-04 | Activadores heteroaromaticos fusionados de la glucoquinasa |
Country Status (21)
Country | Link |
---|---|
US (3) | US6441184B1 (es) |
EP (1) | EP1341774B1 (es) |
JP (1) | JP4109111B2 (es) |
KR (1) | KR100545431B1 (es) |
CN (1) | CN1226294C (es) |
AR (1) | AR031627A1 (es) |
AT (1) | ATE316965T1 (es) |
AU (2) | AU2190202A (es) |
BR (1) | BR0115999A (es) |
CA (1) | CA2429642C (es) |
DE (1) | DE60117059T2 (es) |
DK (1) | DK1341774T3 (es) |
ES (1) | ES2256340T3 (es) |
GT (1) | GT200100243A (es) |
MX (1) | MXPA03005119A (es) |
PA (1) | PA8534301A1 (es) |
PE (1) | PE20020753A1 (es) |
PT (1) | PT1341774E (es) |
UY (1) | UY27055A1 (es) |
WO (1) | WO2002046173A1 (es) |
ZA (1) | ZA200303748B (es) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0102299D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
SE0102764D0 (sv) * | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
CN1678311A (zh) | 2002-06-27 | 2005-10-05 | 诺沃挪第克公司 | 用作治疗剂的芳基羰基衍生物 |
BR0312023A (pt) * | 2002-06-27 | 2005-03-22 | Novo Nordisk As | Composto, composto ativador da glicose cinase, método para evitar a hipoglicemia, uso de um composto, e, composição farmacêutica |
US6775812B2 (en) * | 2002-07-17 | 2004-08-10 | Hewlett-Packard Development Company, L.P. | Layout design process and system for providing bypass capacitance and compliant density in an integrated circuit |
JP4390704B2 (ja) | 2002-10-03 | 2009-12-24 | エフ.ホフマン−ラ ロシュ アーゲー | グルコキナーゼ(gk)活性化物質としてのインドール−3−カルボキシアミド |
MXPA05003559A (es) * | 2002-10-03 | 2005-06-03 | Novartis Ag | (tiazol-2-il)-amida o sulfonamida substituida como activadores de glicocinasa utiles en el tratamiento de diabetes de tipo 2. |
GB0226931D0 (en) * | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
GB0226930D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
MY141521A (en) | 2002-12-12 | 2010-05-14 | Hoffmann La Roche | 5-substituted-six-membered heteroaromatic glucokinase activators |
PL378117A1 (pl) | 2003-02-11 | 2006-03-06 | Prosidion Limited | Tricyklopodstawione związki amidowe |
US7262196B2 (en) * | 2003-02-11 | 2007-08-28 | Prosidion Limited | Tri(cyclo) substituted amide glucokinase activator compounds |
KR100809201B1 (ko) * | 2003-06-20 | 2008-02-29 | 에프. 호프만-라 로슈 아게 | 카나바노이드 수용체 1 역작용제로서 2-아미노벤조티아졸 |
MXPA06007667A (es) | 2004-01-06 | 2006-09-01 | Novo Nordisk As | Heteroaril-ureas y su uso como activadores de glucocinasa. |
WO2005080359A1 (en) * | 2004-02-18 | 2005-09-01 | Astrazeneca Ab | Benzamide derivatives and their use as glucokinae activating agents |
WO2005080360A1 (en) * | 2004-02-18 | 2005-09-01 | Astrazeneca Ab | Compounds |
CA2561157A1 (en) * | 2004-04-02 | 2005-10-13 | Novartis Ag | Thiazolopyridine derivatives, pharmaceutical conditions containing them and methods of treating glucokinase mediated conditions |
JP4700684B2 (ja) * | 2004-04-02 | 2011-06-15 | ノバルティス アーゲー | 2型糖尿病の処置に有用なグルコキナーゼアクティベーターとしてのスルホンアミド−チアゾロピリジン誘導体 |
NZ550567A (en) * | 2004-04-21 | 2010-07-30 | Prosidion Ltd | Tri(cyclo) substituted amide compounds |
TW200600086A (en) * | 2004-06-05 | 2006-01-01 | Astrazeneca Ab | Chemical compound |
JP2008509898A (ja) | 2004-08-12 | 2008-04-03 | プロシディオン・リミテッド | 置換されたフェニルアセトアミドおよびグルコキナーゼ活性化剤としてのこれらの使用 |
JP2008516935A (ja) | 2004-10-16 | 2008-05-22 | アストラゼネカ アクチボラグ | フェノキシベンズアミド化合物の製造方法 |
GB0423043D0 (en) * | 2004-10-16 | 2004-11-17 | Astrazeneca Ab | Compounds |
GB0423044D0 (en) * | 2004-10-16 | 2004-11-17 | Astrazeneca Ab | Compounds |
EP1810969B1 (en) * | 2004-11-02 | 2013-08-07 | Msd K.K. | Aryloxy-substituted benzimidazole derivatives |
DE102005012872A1 (de) * | 2005-03-19 | 2006-09-28 | Sanofi-Aventis Deutschland Gmbh | Substituierte, bizyklische 8-Pyrrolidino-benzimidazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
WO2006125958A1 (en) * | 2005-05-24 | 2006-11-30 | Astrazeneca Ab | 2-phenyl substituted imidazol [4 , 5b] pyridine/ pyrazine and purine derivatives as glucokinase modulators |
TW200714597A (en) * | 2005-05-27 | 2007-04-16 | Astrazeneca Ab | Chemical compounds |
EP2027113A1 (en) * | 2005-07-09 | 2009-02-25 | AstraZeneca AB | Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes |
EP2301929A1 (en) * | 2005-07-09 | 2011-03-30 | AstraZeneca AB (Publ) | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes |
EP1910350A1 (en) * | 2005-07-09 | 2008-04-16 | AstraZeneca AB | 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes |
US7994331B2 (en) | 2005-07-13 | 2011-08-09 | Msd K.K. | Heterocycle-substituted benzimidazole derivative |
US9202182B2 (en) * | 2005-08-11 | 2015-12-01 | International Business Machines Corporation | Method and system for analyzing business architecture |
JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
WO2007039177A2 (en) | 2005-09-29 | 2007-04-12 | Sanofi-Aventis | Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals |
GT200600429A (es) * | 2005-09-30 | 2007-04-30 | Compuestos organicos | |
GT200600428A (es) * | 2005-09-30 | 2007-05-21 | Compuestos organicos | |
EP1948644A1 (en) * | 2005-11-03 | 2008-07-30 | Prosidion Limited | Tricyclo substituted amides |
US20070197532A1 (en) * | 2005-11-18 | 2007-08-23 | Cao Sheldon X | Glucokinase activators |
TW200738621A (en) * | 2005-11-28 | 2007-10-16 | Astrazeneca Ab | Chemical process |
AT503354B1 (de) * | 2006-02-22 | 2008-07-15 | Dsm Fine Chem Austria Gmbh | Verfahren zur herstellung von 3,4-disubstituierten phenylessigsäuren, sowie neue zwischenverbindungen |
JP5302012B2 (ja) | 2006-03-08 | 2013-10-02 | タケダ カリフォルニア インコーポレイテッド | グルコキナーゼ活性剤 |
PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
EP2049518B1 (en) | 2006-05-31 | 2011-08-31 | Takeda San Diego, Inc. | Indazole and isoindole derivatives as glucokinase activating agents. |
US7888504B2 (en) | 2006-07-06 | 2011-02-15 | Bristol-Myers Squibb Company | Glucokinase activators and methods of using same |
US7910747B2 (en) | 2006-07-06 | 2011-03-22 | Bristol-Myers Squibb Company | Phosphonate and phosphinate pyrazolylamide glucokinase activators |
JP2009544648A (ja) | 2006-07-24 | 2009-12-17 | エフ.ホフマン−ラ ロシュ アーゲー | グルコキナーゼ活性化剤としてのピラゾール類 |
TW200825063A (en) * | 2006-10-23 | 2008-06-16 | Astrazeneca Ab | Chemical compounds |
CL2007003061A1 (es) * | 2006-10-26 | 2008-08-01 | Astrazeneca Ab | Compuestos derivados de 3,5-dioxi-benzamida; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad mediada a traves de glk, tal como la diabetes tipo 2. |
US8163779B2 (en) | 2006-12-20 | 2012-04-24 | Takeda San Diego, Inc. | Glucokinase activators |
US20100094009A1 (en) * | 2006-12-21 | 2010-04-15 | Mccabe James | Novel crystalline compound useful as glk activator |
TW200831081A (en) | 2006-12-25 | 2008-08-01 | Kyorin Seiyaku Kk | Glucokinase activator |
JP5248477B2 (ja) | 2007-03-07 | 2013-07-31 | 杏林製薬株式会社 | グルコキナーゼ活性化物質 |
WO2008116107A2 (en) | 2007-03-21 | 2008-09-25 | Takeda San Diego, Inc. | Piperazine derivatives as glucokinase activators |
TW200934772A (en) * | 2008-01-15 | 2009-08-16 | Lilly Co Eli | Crystalline(R)-2-(4-cyclopropanesulphonyl-phenyl)-N-pyrazin-2-yl-3-(tetrahydropyran-4-yl)-propionamide |
TW200942239A (en) | 2008-01-18 | 2009-10-16 | Astellas Pharma Inc | Phenylacetamide derivatives |
US8258134B2 (en) | 2008-04-16 | 2012-09-04 | Hoffmann-La Roche Inc. | Pyridazinone glucokinase activators |
US7741327B2 (en) | 2008-04-16 | 2010-06-22 | Hoffmann-La Roche Inc. | Pyrrolidinone glucokinase activators |
MY163114A (en) | 2008-04-28 | 2017-08-15 | Kyorin Seiyaku Kk | Cyclopentylacrylamide derivative |
AR072900A1 (es) | 2008-08-04 | 2010-09-29 | Astrazeneca Ab | Agentes terapeuticos derivados de pirazolo[3,4-d]pirimidina |
ES2610882T3 (es) * | 2008-08-19 | 2017-05-03 | Janssen Pharmaceutica, N.V. | Antagonistas del receptor al mentol frío |
JP4907746B2 (ja) * | 2008-09-11 | 2012-04-04 | ファイザー・インク | ヘテロアリールアミド誘導体およびグルコキナーゼ活性化因子としてのその使用 |
GB0902434D0 (en) * | 2009-02-13 | 2009-04-01 | Astrazeneca Ab | Chemical process |
GB0902406D0 (en) * | 2009-02-13 | 2009-04-01 | Astrazeneca Ab | Crystalline polymorphic form |
NZ595024A (en) | 2009-03-11 | 2013-01-25 | Pfizer | Benzofuranyl derivatives used as glucokinase inhibitors |
AR076220A1 (es) | 2009-04-09 | 2011-05-26 | Astrazeneca Ab | Derivados de pirazol [4,5 - e] pirimidina |
AR076221A1 (es) | 2009-04-09 | 2011-05-26 | Astrazeneca Ab | Derivado de pirazol [4,5-e] pirimidina y su uso para tratar diabetes y obesidad |
US8222416B2 (en) * | 2009-12-14 | 2012-07-17 | Hoffmann-La Roche Inc. | Azaindole glucokinase activators |
CN105176930B (zh) | 2010-03-31 | 2021-05-04 | 斯克里普斯研究所 | 重编程细胞 |
WO2012027331A1 (en) | 2010-08-27 | 2012-03-01 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
CA2828346C (en) | 2011-03-01 | 2021-01-26 | Synergy Pharmaceuticals Inc. | Process of preparing guanylate cyclase c agonists |
ES2489297B1 (es) | 2013-01-22 | 2015-06-10 | Consejo Superior De Investigaciones Científicas (Csic) | Benzotiazoles sustituidos y sus aplicaciones terapeuticas para el tratamiento de enfermedades humanas |
JP6606491B2 (ja) | 2013-06-05 | 2019-11-13 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼcの超高純度アゴニスト、その作成および使用方法 |
EP2878339A1 (en) | 2013-12-02 | 2015-06-03 | Siena Biotech S.p.A. | SIP3 antagonists |
RU2021109549A (ru) | 2014-08-29 | 2021-05-13 | Тес Фарма С.Р.Л. | ИНГИБИТОРЫ α-АМИНО-β-КАРБОКСИМУКОНАТ ε-СЕМИАЛЬДЕГИД-ДЕКАРБОКСИЛАЗЫ |
BR112017024517A2 (pt) | 2015-05-15 | 2018-07-24 | Aurigene Discovery Technologies Limited | compostos de tetraidroquinolinona como moduladores ror gama |
AR109950A1 (es) | 2016-10-14 | 2019-02-06 | Tes Pharma S R L | INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA |
CA3093025A1 (en) | 2018-06-12 | 2019-12-19 | Vtv Therapeutics Llc | Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs |
AU2019385644A1 (en) | 2018-11-20 | 2021-06-03 | Tes Pharma S.R.L. | Inhibitors of α-Amino-β-carboxymuconic acid semialdehyde decarboxylase |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3840550A (en) * | 1971-05-24 | 1974-10-08 | Ciba Geigy Corp | Certain 6-isothiocyanobenzothiazoles |
US6320050B1 (en) * | 1999-03-29 | 2001-11-20 | Hoffmann-La Roche Inc. | Heteroaromatic glucokinase activators |
BR0009486B1 (pt) * | 1999-03-29 | 2011-03-09 | composto que compreende uma amida, composição farmacêutica que compreende esse composto, seu uso e processo para a preparação do mesmo. |
-
2001
- 2001-11-28 ES ES01999565T patent/ES2256340T3/es not_active Expired - Lifetime
- 2001-11-28 KR KR1020037007517A patent/KR100545431B1/ko not_active IP Right Cessation
- 2001-11-28 WO PCT/EP2001/013870 patent/WO2002046173A1/en active IP Right Grant
- 2001-11-28 CA CA002429642A patent/CA2429642C/en not_active Expired - Fee Related
- 2001-11-28 BR BR0115999-2A patent/BR0115999A/pt not_active IP Right Cessation
- 2001-11-28 DE DE60117059T patent/DE60117059T2/de not_active Expired - Lifetime
- 2001-11-28 EP EP01999565A patent/EP1341774B1/en not_active Expired - Lifetime
- 2001-11-28 JP JP2002547912A patent/JP4109111B2/ja not_active Expired - Fee Related
- 2001-11-28 DK DK01999565T patent/DK1341774T3/da active
- 2001-11-28 PT PT01999565T patent/PT1341774E/pt unknown
- 2001-11-28 AU AU2190202A patent/AU2190202A/xx active Pending
- 2001-11-28 AU AU2002221902A patent/AU2002221902B2/en not_active Ceased
- 2001-11-28 CN CNB018194494A patent/CN1226294C/zh not_active Expired - Fee Related
- 2001-11-28 AT AT01999565T patent/ATE316965T1/de not_active IP Right Cessation
- 2001-12-04 US US10/006,168 patent/US6441184B1/en not_active Expired - Fee Related
- 2001-12-04 PE PE2001001217A patent/PE20020753A1/es not_active Application Discontinuation
- 2001-12-04 US US10/007,091 patent/US6448399B1/en not_active Expired - Fee Related
- 2001-12-04 AR ARP010105639A patent/AR031627A1/es unknown
- 2001-12-04 US US10/006,170 patent/US6545155B2/en not_active Expired - Fee Related
- 2001-12-04 PA PA20018534301A patent/PA8534301A1/es unknown
- 2001-12-05 GT GT200100243A patent/GT200100243A/es unknown
- 2001-12-05 UY UY27055A patent/UY27055A1/es not_active Application Discontinuation
-
2003
- 2003-05-14 ZA ZA200303748A patent/ZA200303748B/en unknown
- 2003-06-06 MX MXPA03005119A patent/MXPA03005119A/es active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
CN1476438A (zh) | 2004-02-18 |
WO2002046173A1 (en) | 2002-06-13 |
PA8534301A1 (es) | 2002-08-26 |
CA2429642A1 (en) | 2002-06-13 |
AU2190202A (en) | 2002-06-18 |
US20020103241A1 (en) | 2002-08-01 |
CA2429642C (en) | 2007-11-20 |
GT200100243A (es) | 2002-06-04 |
JP2004517087A (ja) | 2004-06-10 |
KR100545431B1 (ko) | 2006-01-24 |
CN1226294C (zh) | 2005-11-09 |
PE20020753A1 (es) | 2002-08-27 |
US20020107396A1 (en) | 2002-08-08 |
EP1341774A1 (en) | 2003-09-10 |
ES2256340T3 (es) | 2006-07-16 |
US20020103199A1 (en) | 2002-08-01 |
US6441184B1 (en) | 2002-08-27 |
KR20030068555A (ko) | 2003-08-21 |
US6545155B2 (en) | 2003-04-08 |
ATE316965T1 (de) | 2006-02-15 |
BR0115999A (pt) | 2003-09-30 |
DK1341774T3 (da) | 2006-06-12 |
PT1341774E (pt) | 2006-05-31 |
ZA200303748B (en) | 2004-08-16 |
US6448399B1 (en) | 2002-09-10 |
JP4109111B2 (ja) | 2008-07-02 |
DE60117059D1 (de) | 2006-04-13 |
EP1341774B1 (en) | 2006-02-01 |
MXPA03005119A (es) | 2004-10-15 |
AU2002221902B2 (en) | 2006-11-23 |
UY27055A1 (es) | 2002-07-31 |
DE60117059T2 (de) | 2006-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR031627A1 (es) | Activadores heteroaromaticos fusionados de la glucoquinasa | |
ES2193607T3 (es) | Derivados de benzosulfona . | |
DK1585739T3 (da) | Substituerede arylcyclopropylacetamider som glucokinaseaktivatorer | |
PE20011287A1 (es) | Derivados de imidazopirimidina y derivados de triazolopirimidina | |
CO5590895A2 (es) | Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos | |
PE20030746A1 (es) | DERIVADOS DE PIRIDO [2,1-a] ISOQUINOLINA | |
PA8516401A1 (es) | Inhibidores de la replicacion del hiv | |
UY26899A1 (es) | Derivados de pirazol fusionados | |
EA200600925A1 (ru) | Производные триазола в качестве антагонистов вазопрессина | |
AR068413A2 (es) | Derivados 8-amino, metodos de preparacion, composiciones farmaceuticas y su uso en terapia | |
ATE302775T1 (de) | Carbolinderivate | |
EA200600348A1 (ru) | Новые соединения | |
NO931366D0 (no) | 1,2,4-oksadiazolylfenoksyalkylisoksazoler og deres anvendelse som antivirale midler | |
DE60230127D1 (de) | Inhibitoren von integrin alpha-v-beta-6 | |
ATE346067T1 (de) | Carbolinderivate | |
HRP20070286T3 (en) | Substituted diketopiperazines and their use as oxytocyn antagonists | |
ATE300543T1 (de) | Kondensierte pyrazindionderivate als pde5 inhibitore | |
FI935517A0 (fi) | Fenoxi- och fenoxialkylpiperidiner som virusmotverkande medel | |
NO20052023L (no) | Kalsium aktivert K kanal apner med hoy konduktans | |
DE60112960D1 (de) | Kondensierte pyridoindolderivate | |
ATE333457T1 (de) | Zyklische gmp-spezifische phosphodiesteraseinhibitoren | |
CO5611130A2 (es) | Nuevos derivados oxazol, su fabricacion y uso como agentes farmaceuticos | |
CO5261560A1 (es) | Nuevos derivados de tiazolidindiona como agentes antidiabeticos | |
TR200200969T2 (tr) | Karbonilamino türevlerinin CNS bozukluklarına karşı kullanılması | |
ATE330958T1 (de) | Pyrazino 1'2':1,6öpyrido 3,4-böindolderivate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |